498 related articles for article (PubMed ID: 29985080)
1. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
2. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
[TBL] [Abstract][Full Text] [Related]
3. Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial.
Raft MB; Hetland ML; Brahe CH; Hørslev-Petersen K; Midtbøll Ørnbjerg L; Junker P; Biln N; Stengaard-Pedersen K; Østergaard M
Scand J Rheumatol; 2023 Jul; 52(4):342-352. PubMed ID: 35833274
[TBL] [Abstract][Full Text] [Related]
4. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.
Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW
Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF
Ann Rheum Dis; 2015 Jun; 74(6):1102-9. PubMed ID: 24812287
[TBL] [Abstract][Full Text] [Related]
6. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage.
Krabbe S; Bolce R; Brahe CH; Døhn UM; Ejbjerg BJ; Hetland ML; Sasso EH; Chernoff D; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller J; Østergaard M
Scand J Rheumatol; 2017 Sep; 46(5):353-358. PubMed ID: 27682742
[TBL] [Abstract][Full Text] [Related]
7. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression.
van der Helm-van Mil AH; Knevel R; Cavet G; Huizinga TW; Haney DJ
Rheumatology (Oxford); 2013 May; 52(5):839-46. PubMed ID: 23287359
[TBL] [Abstract][Full Text] [Related]
9. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
10. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
11. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
[TBL] [Abstract][Full Text] [Related]
12. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
Curtis JR; Brahe CH; Østergaard M; Lund Hetland M; Hambardzumyan K; Saevarsdottir S; Wang X; Flake Ii DD; Sasso EH; Huizinga TW
Curr Med Res Opin; 2019 Sep; 35(9):1483-1493. PubMed ID: 30777458
[No Abstract] [Full Text] [Related]
13. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
14. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
Hetland ML; Stengaard-Pedersen K; Junker P; Østergaard M; Ejbjerg BJ; Jacobsen S; Lottenburger T; Hansen I; Tarp U; Andersen LS; Svendsen A; Pedersen JK; Lauridsen UB; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Hørslev-Petersen K;
Ann Rheum Dis; 2010 Oct; 69(10):1789-95. PubMed ID: 20444751
[TBL] [Abstract][Full Text] [Related]
15. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
[TBL] [Abstract][Full Text] [Related]
16. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
Ørnbjerg LM; Østergaard M; Jensen T; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Hetland ML; ; Slot O; Nielsen LK; Skjødt H; Majgaard O; Lorenzen T; Horn HC; Kowalski M; Johansen IL; Pedersen PM; Manilo N; Bliddal H
Clin Rheumatol; 2017 Apr; 36(4):781-789. PubMed ID: 27921185
[TBL] [Abstract][Full Text] [Related]
17. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
[TBL] [Abstract][Full Text] [Related]
18. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
19. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study.
Markusse IM; Dirven L; van den Broek M; Bijkerk C; Han KH; Ronday HK; Bolce R; Sasso EH; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
J Rheumatol; 2014 Nov; 41(11):2114-9. PubMed ID: 25128518
[TBL] [Abstract][Full Text] [Related]
20. Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis.
Hetland ML; Østergaard M; Stengaard-Pedersen K; Junker P; Ejbjerg B; Jacobsen S; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Krogh NS; Hørslev-Petersen K;
Scand J Rheumatol; 2019 Jan; 48(1):1-8. PubMed ID: 30101636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
